scholarly journals Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real‐life data

2020 ◽  
Vol 148 (2) ◽  
pp. 296-306
Author(s):  
Patricia A. H. Hamers ◽  
Marloes A. G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne M. May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Real Life ◽  
Life Data ◽  
Real Life Data ◽  
Colorectal Cancer Patients ◽  
Multiple Scenarios

Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival based on real-life data.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 32-32
Author(s):  
Patricia Hamers ◽  
Marloes A.G. Elferink ◽  
Rebecca K. Stellato ◽  
Cornelis J. A. Punt ◽  
Anne Maria May ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Systemic Therapy ◽  
Total Population ◽  
Real Life ◽  
Case Scenario ◽  
Worst Case ◽  
Life Data ◽  
Real Life Data ◽  
Multiple Scenarios

32 Background: Reported median overall survival (mOS) in trials of metastatic colorectal cancer (mCRC) patients receiving systemic therapy has increased to over 30 months. When informing patients, many clinicians quote the mOS reported in these trials. It is uncertain whether trial results translate to real-life populations. Moreover, patients prefer presentation of multiple survival scenarios over presentation of just mOS. Therefore, we quantified multiple scenarios for survival time of real-life mCRC patients. Methods: Nationwide population-based data of all stage IV CRC patients diagnosed between 2008 and 2016 were obtained from the Netherlands Cancer Registry. We calculated percentiles (scenarios) of OS per year of diagnosis for the total population, and for treatment subgroups: 10th (best-case), 25th (upper-typical), 50th (median), 75th (lower-typical), and 90th (worst-case). Results: The total study population comprised 27,275 patients. Twenty-five percent these patients did not receive any antitumor treatment. From 2008-2016, mOS of the total population remained unchanged at approximately 12 months. OS improved only for the upper-typical and best-case patients; by 4.2 to 29.1 months (p<0.001), and by 6.0 months to 62.0 months (p<0.001), respectively. No clinically relevant change was seen among patients who received systemic therapy, with mOS close to 15 months and best-case scenario approximately 40 months. mOS and worst-case scenario for survival were highest in patients who underwent both metastasectomy and systemic therapy: around 48 and 15 months, respectively. A clinically relevant improvement in survival over time was observed only in patients who initially received metastasectomy without systemic treatment. Conclusions: In contrast to the wide belief that mOS of mCRC patients receiving systemic therapy has improved substantially, improvement could not be demonstrated in our real-life population. Clinicians should consider quoting multiple scenarios for survival based on real-life data, instead of point estimates from clinical trials, when informing patients about their life expectancy.

scholarly journals A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting

PLoS ONE ◽  
2016 ◽  
Vol 11 (5) ◽  
pp. e0154689
Author(s):  
Nava Siegelmann-Danieli ◽  
Ariel Farkash ◽  
Itzhak Katzir ◽  
Janet Vesterman Landes ◽  
Hadas Rotem Rabinovich ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Care ◽  
Care Setting ◽  
Real Life ◽  
Computational Tool ◽  
Life Data ◽  
Data Application ◽  
Real Life Data

scholarly journals Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients

2020 ◽  
Vol 9 (6) ◽  
pp. 1772
Author(s):  
Matthias Unseld ◽  
Sebastian Fischöder ◽  
Mathias Jachs ◽  
Magdalena Drimmel ◽  
Alexander Siebenhüner ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adverse Events ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Surrogate Marker ◽  
University Hospital ◽  
Rank Test ◽  
Line Treatment ◽  
Colorectal Cancer Patients

The nucleoside trifluridine/tipiracil (TAS-102) and the multikinase inhibitor regorafenib significantly improved survival in metastatic colorectal cancer patients (mCRC). Both treatments are characterized by different treatment-related adverse events but detailed analyses of predictive side effects are rare. In this retrospective, observational, real-life study, clinical data on mCRC patients treated with trifluridine/tipiracil or regorafenib at the Medical University of Vienna, Austria and the University Hospital Zurich, Switzerland were collected. The correlation between adverse events and response or survival rates were calculated performing Fisher’s exact test and log-rank test, respectively. Common adverse events of any grade included fatigue (52%), nausea/vertigo (34%), anemia (26%), and leukopenia (22%) in trifluridine/tipiracil patients and fatigue (42%), hand-foot-skin syndrome (36%) and hoarseness (34%) in patients upon regorafenib treatment. In trifluridine/tipiracil patients the prevalence of leukopenia (p = 0.044) and weight loss (p = 0.044) was prognostic, whereas leukopenia (p = 0.044) and neutropenia (p = 0.043) predicted PFS. The disease control rate was not significantly affected. In regorafenib-treated patients, the prevalence of nausea (p = 0.001) was prognostic, while oral mucositis predicted PFS (p = 0.032) as well as the DCR (p = 0.039). In conclusion, we underline the efficacy of trifluridine/tipiracil and regorafenib in the real-life setting. We describe predictive adverse events like neutropenia/leukopenia, which might be used as surrogate marker in anticancer therapy beyond second line treatment.

scholarly journals Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands

2017 ◽  
Vol 23 (3) ◽  
pp. 482-489 ◽  
Author(s):  
Johannes J. M. Kwakman ◽  
G. Vink ◽  
J. H. Vestjens ◽  
L. V. Beerepoot ◽  
J. W. de Groot ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
The Netherlands ◽  
Metastatic Colorectal Cancer ◽  
Real Life ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document